KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI THẦN KINH NỘI TIẾT TẾ BÀO LỚN GIAI ĐOẠN TÁI PHÁT DI CĂN BẰNG PHÁC ĐỒ ETOPOSIDE/CISPLATIN TẠI BỆNH VIỆN K

Abstract

Objective: The research's primary objective were describing the clinical, subclinical features, and evaluating treatment results of cisplatin/etoposide for the treatment of recurrent/ metastatic pulmonary large cells neuroendocrine carcinoma at Vietnam National Cancer Hospital from 1/2018 to 10/2021. Patients and Methods: A retrospective study of 33 patients diagnosed of recurrent/ metastatic pulmonary large cells neuroendocrine carcinoma were treated with Cisplatin/etoposide at Vietnam National Cancer Hospital from 1/2018 to 10/2021. Results: The mean age of the group was 62 years old (range, 35-69). The male/female ratio was 7.26/1. Patients presented with ECOG 1 accounted for 54.5%. Patients with multiple metastatic lesions acquired 81.8%, there were 19 patients presented with N2 metastasis and more than 50% of cases diagnosed of T3 or T4 stage. For response of treatment protocol with etoposide/cisplatin chemotherapy for the treatmet of metastatic lung cancer, the disease control rate was 69.7%. The overall response rate was 42.4%. Conclusion: Cisplatin/etoposide chemotherapy for recurrent/metastatic stages in large cell neuroendocrine lung carcinoma had a high disease control rate with overall response rate of 42.4%.